Eli Lilly Reports Retatrutide Followup Data and Weight Loss Trial Results

Eli Lilly reported new clinical trial findings on an experimental obesity treatment combination involving tirzepatide and eloralintide, showing participants achieved greater weight loss than with tirzepatide alone. The results examined a 48-week treatment period in patients receiving the combination therapy.

According to finance.yahoo.com, patients using both drugs lost up to 23.3% of their body weight, compared with up to 14.8% among those taking tirzepatide alone and 12.3% among those receiving only eloralintide.

The combination treatment pairs tirzepatide, the active ingredient in Zepbound, with eloralintide, an experimental drug that targets amylin, a natural hormone. The approach was tested to determine whether combining different mechanisms could improve weight reduction.

The trial results also showed a higher rate of treatment discontinuation among participants receiving the combination therapy. According to finance.yahoo.com, discontinuation reached as high as 27%, with side effects cited as a concern.

Eli Lilly Cardiometabolic Health President Ken Custer said high discontinuation rates were also observed for tirzepatide during its mid-stage development years earlier. The company continues evaluating dosing strategies and treatment approaches.

Eli Lilly has expanded its obesity drug pipeline while maintaining its position in the GLP-1 market. According to finance.yahoo.com, the company reported a market capitalization above $1 trillion and shares had risen around 10% during the year.